PATENT CLAIM ANALYSIS

Application Number: 16034906
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["435", "257200"]

Abstract:
Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.

Claim (Index 50):
The Gram-negative bacterium of  claim 31 , wherein the polysaccharide is an O antigen of  E. coli  (O1, O2, O3, O4, O5, O6, O7, O8, O9, O10, O11, O12, O13, O14, O15, O16, O17, O18, O19, O20, O21, O22, O23, O24, O25, O26, O27, O28, O29, O30, O32, O33, O34, O35, O36, O37, O38, O39, O40, O41, O42, O43, O44, O45, O46, O48, O49, O50, O51, O52, O53, O54, O55, O56, O57, O58, O59, O60, O61, O62, O63, O64, O65, O66, O68, O69, O70, O71, O73, O74, O75, O76, O77, O78, O79, O80, O81, O82, O83, O84, O85, O86, O87, O88, O89, O90, O91, O92, O93, O95, O96, O97, O98, O99, O100, O101, O102, O103, O104, O105, O106, O107, O108, O109, O110, O111, O112, O113, O114, O115, O116, O117, O118, O119, O120, O121, O123, O124, O125, O126, O127, O128, O129, O130, O131, O132, O133, O134, O135, O136, O137, O138, O139, O140, O141, O142, O143, O144, O145, O146, O147, O148, O149, O150, O151, O152, O153, O154, O155, O156, O157, O158, O159, O160, O161, O162, O163, O164, O165, O166, O167, O168, O169, O170, O171, O172, O173, O174, O175, O176, O177, O178, O179, O180, O181, O182, O183, O184, O185, O186, O187),  Salmonella  sp ( S. enterica  subsp. Enterica,  S. enterica  subsp. Salamae,  S. enterica  subsp. arizonae,  S. enterica  subsp. Diarizonae,  S. enterica  subsp. Houtenae,  S. bongori , and  S. enterica  subsp. Indica, and O types 1-67, Pseudomonas sp ( P. aeruginosa  O serotypes 1-20), Klebsiella sp. (particularly K.  pneumonia  serotypes O1, O2 (and subserotypes), O3, O4, O5, O6, O7, O8, O9, O10, O11, O12), Acinetobacter O antigens (in particular  A. baumannii  O antigens),  Chlamydia trachomatis  O antigens (serotypes A, B, C, D, E, F, G, H, I J, K, L1, L2, L3),  Vibrio cholera  O antigens O1 to 155, Listeria sp., in particular  L. monocytogenes  type 1, 2, 3, 4 and subserotypes thereof,  Legionella pneumophila  serotypes 1 to 15 O antigens,  Bordetella parapertussis  O antigens,  Burkholderia mallei  and  pseudomallei  O antigens,  Francisella tularensis , Campylobacter sp. ( C. jejuni ); Capsular polysaccharides of  Clostridium difficile  (serotypes A, G, H, K, S1, S4, D, Cd-5, and  C. perfringens  serotypes A, B, C, D and E),  Staphylococcus aureus  type 5 and 8,  Streptococcus pyrogenes  (group B streptococcus capsular serotype polysaccharides),  E. coli, Streptococcus agalacticae  (group A streptococcal capsular polysaccharides),  Neisseria meningitidis  (serotypes A, B, C, W, Y, X),  Candida albicans, Haemophilus influenza, Enterococcus faecalis  capsular polysaccharides type I-V; and other surface polysaccharide structures, e.g. the  Borrelia burgdorferi  glycolipids),  Neisseria meningitidis  pilin O glycan and lipooligosaccharide (LOS),  Haemophilus influenza  LOS, Leishmania major lipophosphoglycan, tumor associated carbohydrate antigens, malaria glycosyl phosphatidylinositol, or mycobacterium tuberculosis arabinomannan.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 95.0
- Lexical Diversity: 1.4375
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14494150', '15414900', '13100603', '15502748', '15553733']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6437179613894191
- 35 USC 102 Novelty (BERT): 0.5379771412904605
- Combined Prediction Score: 0.6331438793795232
- Mean Citation Score: 377.37043000000006
- Max Citation Score: 400.89948
- Similarity Product: 240.570427134018

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test